One key element is the anticipated Phase 3 MAPLE-HCM data, expected in the first half of 2025, which is seen as a critical catalyst for aficamten’s expanded use. The drug aims to become the ...

The financial terms of the deal were not discosed. Aficamten is an investigational selective, small molecule cardiac myosin inhibitor for the potential treatment of patients with HCM. CORXEL ...

Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, ...

Like any other informed investor, we are always on the hunt for stocks that analysts are talking about. Analysts use their in ...

Stifel analysts initiated coverage on Cytokinetics shares (NASDAQ:CYTK), assigning a Buy rating and setting a price target of ...

The company’s strategic direction for 2025 and beyond is underpinned by significant milestones, particularly the anticipated approval of aficamten for obstructive HCM patients. This potential ...

Stifel has initiated coverage of Cytokinetics (NASDAQ:CYTK) with a buy rating, citing its drug aficamten. The bank noted the stock was "out of favor" in the wake of a "controversial" deal with ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline ...

The company's lead candidate, aficamten, has been advancing steadily through the regulatory process. Cytokinetics is on track to complete its New Drug Application (NDA) submission to the U.S. Food and ...

Stifel analyst James Condulis writes Cytokinetics’ aficamten is an exceptional drug as it sets a strong competitive standard for a multi-billion-dollar obstructive hypertrophic cardiomyopathy ...

Cytokinetics is on track to submit a New Drug Application (NDA) for aficamten in obstructive HCM (oHCM) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2024. This timeline is ...